Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis

Table 1 Patients’ characteristics

	Landiolol	Control
n	39	22
Age, yr	70.7 ± 12.3	70.8 ± 12.5
Underlying disease
Cardiovascular disease	16 (41.0%)	11 (50.0%)
Malignancy	11 (28.2%)	3 (13.6%)
Immunological disorder	3 (7.7%)	2 (9.1%)
Others	9 (23.1%)	6 (27.2%)
Infected site
Respiratory tract	17 (43.6%)	14 (63.6%)
Intra-abdominal	13 (33.3%)a	2 (9.1%)
Blood	5 (12.8%)	0 (0%)
Skin/soft tissue	2 (5.1%)	0 (0%)
Urinary tract	1 (2.6%)a	4 (18.2%)
Others	1 (2.6%)	2 (9.1%)
APACHE II	22.8 ± 5.4	22.1 ± 7.7
SOFA	8.8 ± 4.0	9.1 ± 3.9

^aP < 0.05 vs control. APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment.